Send to

Choose Destination
Hum Mol Genet. 2018 Nov 15;27(22):3870-3880. doi: 10.1093/hmg/ddy278.

Rescue of biosynthesis of nicotinamide adenine dinucleotide protects the heart in cardiomyopathy caused by lamin A/C gene mutation.

Author information

Sorbonne Université, UPMC Paris 06, INSERM UMRS974, Center of Research in Myology, Institut de Myologie, Paris, France.
INSERM UMR-S 1180 - LabEx LERMIT - DHU TORINO, Institut Paris-Saclay d'Innovation Therapeutique (IPSIT-US31-UMS3679), Faculty of Pharmacy, Univ Paris-Sud, Université Paris-Saclay, Chatenay-Malabry, France.
Sorbonne Université, UPMC Paris 06, INSERM UMS28 Phénotypage du petit animal, Faculté de Médecine Pierre et Marie Curie, Paris, France.
Cardiology Department, Cochin Hospital, Filière Neuromusculaire, Paris-Descartes University, Sorbonne Paris Cité University, Assistance Publique-Hôpitaux de Paris, Paris, France.


Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is an anatomic and pathologic condition associated with muscle and electrical dysfunction of the heart, often leading to heart failure-related disability. There is currently no specific therapy available for patients that target the molecular pathophysiology of LMNA cardiomyopathy. Recent studies suggested that nicotinamide adenine dinucleotide (NAD+) cellular content could be a critical determinant for heart function. Biosynthesis of NAD+ from vitamin B3 (known as salvage pathways) is the primary source of NAD+. We showed here that NAD+ salvage pathway was altered in the heart of mouse and human carrying LMNA mutation, leading to an alteration of one of NAD+ co-substrate enzymes, PARP-1. Oral administration of nicotinamide riboside, a natural NAD+ precursor and a pyridine-nucleoside form of vitamin B3, leads to a marked improvement of the NAD+ cellular content, an increase of PARylation of cardiac proteins and an improvement of left ventricular structure and function in a model of LMNA cardiomyopathy. Collectively, our results provide mechanistic and therapeutic insights into dilated cardiomyopathy caused by LMNA mutations.

Free full text

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for HAL archives ouvertes
Loading ...
Support Center